Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Apo-Si-K170A-C76 in Healthy Subjects
NCT07095049Phase 1Active, not recruiting
- Sponsor
- Interna Therapeutics
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Apo-Si-K170A-C76 with Placebo (2 arms). Primary endpoints: Safety and tolerability evaluated by Adverse Events (AEs) at 5 days, Safety and tolerability evaluated by Treatment-Emergent Adverse Events (TEAEs) at 5 days and 5 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
Apo-Si-K170A-C76
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07095049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095049.